Product Datasheet

Hormone-sensitive Lipase/HSL [p Ser660] Antibody - Azide and BSA Free

NBP3-05459

Unit Size: 100 ul

Store at -20C. Avoid freeze-thaw cycles.



NBP3-05459

Hormone-sensitive Lipase/HSL [p Ser660] Antibody - Azide and BSA Free

Product Information

Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.3), 50% glycerol

Product Description

Description	Novus Biologicals Rabbit Hormone-sensitive Lipase/HSL [p Ser660] Antibody - Azide and BSA Free (NBP3-05459) is a polyclonal antibody validated for use in WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	3991
Gene Symbol	LIPE
Species	Human, Mouse
Immunogen	A synthetic phosphorylated peptide around S660 of human Hormone-sensitive Lipase/HSL (NP_005348.2). QTSRS

Product Application Details

Applications	Western Blot
Recommended Dilutions	Western Blot 1:500 - 1:1000

Images

Western Blot: Hormone-sensitive Lipase/HSL [p Ser660] Antibody [NBP3-05459] - Analysis of extracts of NIH/3T3 cells, using Phospho-HSL-S660 antibody at 1:1000 dilution.NIH/3T3 cells were treated by Forskolin (10 uM) at 37c for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Basic Kit. Exposure time: 180s.



Ablation of ASC in stromal vascular fractions (SVF) cells improved the lipogenesis but impaired lipolysis. (a–d) Primary SAT SVF cells of LM and Asc−/− mice (Red-LM mice, Blue-Asc−/− mice). (a) Oil Red O staining of the 6th day under lipogenesis inducement treated primary SAT SVF cells, separated from LM and Asc−/− mice, scale bar 200 um. (b) The expression of lipogenesis genes was analyzed by RT-qPCR. (c) Expression of lipogenesis (ACC, FASN, FABP4) and lipolysis (p-HSL, HSL, ATGL) protein in indicated cells. (d–h) Primary SAT SVF cells separated from WT mice were transfected with siRNA targeting for ASC on the 4th day (Blue-NC, Yellow-si Asc). (d,e) mRNA and protein level of ASC in indicated cells. (f) Oil Red O staining of the 6th day under lipogenesis inducement treated in indicated cells, scale bar 200 um. (g) Expression of lipogenesis genes in indicated cells. (h) Expression of lipogenesis (ACC, FASN, FABP4) and lipolysis (p-HSL, HSL, ATGL) protein in indicated cells. Data are presented as means +/- SD from three independent experiments. * $p < 0.05$ and ** $p < 0.01$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36077447), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Ablation of ASC in stromal vascular fractions (SVF) cells improved the lipogenesis but impaired lipolysis. (a–d) Primary SAT SVF cells of LM and Asc−/− mice (Red-LM mice, Blue-Asc−/− mice). (a) Oil Red O staining of the 6th day under lipogenesis inducement treated primary SAT SVF cells, separated from LM and Asc−/− mice, scale bar 200 um. (b) The expression of lipogenesis genes was analyzed by RT-qPCR. (c) Expression of lipogenesis (ACC, FASN, FABP4) and lipolysis (p-HSL, HSL, ATGL) protein in indicated cells. (d–h) Primary SAT SVF cells separated from WT mice were transfected with siRNA targeting for ASC on the 4th day (Blue-NC, Yellow-si Asc). (d,e) mRNA and protein level of ASC in indicated cells. (f) Oil Red O staining of the 6th day under lipogenesis inducement treated in indicated cells, scale bar 200 um. (g) Expression of lipogenesis genes in indicated cells. (h) Expression of lipogenesis (ACC, FASN, FABP4) and lipolysis (p-HSL, HSL, ATGL) protein in indicated cells. Data are presented as means +/- SD from three independent experiments. * $p < 0.05$ and ** $p < 0.01$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36077447), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Increased lipogenesis and decreased lipolysis were observed in subcutaneous adipose tissue of Asc−/− mice fed with HFD. (a) Body weight change of LM (n = 8/group) and Asc knockout (Asc−/−) mice (n = 10/group), fed with HFD (12 weeks). (b) SAT groups are as described in (a). (c) Fat index (ratio of SAT weight to whole body weight of indicated mice. (d) H&E and quantification of SAT cell size, scale bar 50 um. (e,f) GTT and ITT analysis of indicated mice. (g) In indicated mice, plasma concentrations of triglyceride (TG), total cholesterol (TC), and free fatty acids (NEFA) at baseline. (h) mRNA expression of lipogenesis genes in SAT from indicated mice. (i) Western blot analysis of lipogenesis (ACC, FASN, FABP4) and lipolysis (p-HSL, HSL, ATGL) proteins in SAT. All the mice were male and fed with HFD for 12 weeks if not indicated otherwise. (n = 8–10/group) (Red-LM mice, Blue-Asc−/− mice). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36077447), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



OA improves glucose and lipid metabolism and alleviates diet-induced IR. (A) Body weight of mice in vehicle, 25 mg/kg OA, 50 mg/kg OA group at the end of the experiment (n = 7). (B) Glucose tolerance test (GTT) in mice after 4 weeks of OA treatment (n = 7). (C) Fasting plasma insulin levels (n = 7). (D) HOMA-IR index (n = 7). (E) Western blots of phospho-Ser473 Akt (p-Akt), and Akt in eWAT of mice. (F) Plasma concentrations of triglyceride, total cholesterol, FFA at baseline (fasted), and Adipo-IR index (n = 5–7). (G) Western blots of phospho-Ser660 HSL (p-HSL), and HSL in the eWAT of mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34393781), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP3-05459

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP3-05459

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications